Melphalan

Generic Name
Melphalan
Brand Names
Alkeran, Evomela, Phelinun, Pepaxti
Drug Type
Small Molecule
Chemical Formula
C13H18Cl2N2O2
CAS Number
148-82-3
Unique Ingredient Identifier
Q41OR9510P
Background

Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is...

Indication

Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
...

Associated Conditions
Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy
Clinical Trials
Related News

Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers

First Posted Date
2003-04-18
Last Posted Date
2014-01-06
Lead Sponsor
Medical College of Wisconsin
Target Recruit Count
10
Registration Number
NCT00003163
Locations
🇺🇸

Medical College of Wisconsin, Milwaukee, Wisconsin, United States

High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

Phase 3
Completed
Conditions
Leukemia
First Posted Date
2003-04-16
Last Posted Date
2012-04-13
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
61
Registration Number
NCT00002945
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Combination Chemotherapy in Treating Patients With Lymphoma

First Posted Date
2003-04-16
Last Posted Date
2018-11-15
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
116
Registration Number
NCT00002835
Locations
🇺🇸

University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma

First Posted Date
2003-04-10
Last Posted Date
2013-12-19
Lead Sponsor
Medical Research Council
Target Recruit Count
1000
Registration Number
NCT00002653
Locations
🇬🇧

MRC Myelomatosis Trials Office, Birmingham, England, United Kingdom

Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

First Posted Date
2003-04-09
Last Posted Date
2012-06-01
Lead Sponsor
Northwestern University
Target Recruit Count
44
Registration Number
NCT00058292
Locations
🇺🇸

Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

🇺🇸

Hematology-Oncology Associates of Illinois, Chicago, Illinois, United States

🇺🇸

Mayo Clinic Cancer Center, Rochester, Minnesota, United States

Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

First Posted Date
2003-03-07
Last Posted Date
2011-03-07
Lead Sponsor
Roswell Park Cancer Institute
Registration Number
NCT00055653
Locations
🇺🇸

Children's Hospital Los Angeles, Los Angeles, California, United States

🇺🇸

Children's Hospital of Orange County, Orange, California, United States

🇺🇸

North Shore University Hospital, Manhasset, New York, United States

and more 22 locations

Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

First Posted Date
2003-02-06
Last Posted Date
2017-10-16
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
16
Registration Number
NCT00054353
Locations
🇮🇹

University of Torino, Torino, Italy

🇺🇸

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma

First Posted Date
2003-01-27
Last Posted Date
2013-05-31
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
312
Registration Number
NCT00002556
Locations
🇺🇸

Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma

First Posted Date
2003-01-27
Last Posted Date
2013-05-17
Lead Sponsor
Children's Oncology Group
Target Recruit Count
495
Registration Number
NCT00004188
Locations
🇺🇸

Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States

🇺🇸

Marshfield Clinic - Marshfield Center, Marshfield, Wisconsin, United States

🇺🇸

Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States

and more 93 locations

Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer

First Posted Date
2003-01-27
Last Posted Date
2013-03-07
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Registration Number
NCT00014469
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy